Artelo Biosciences, Inc. (NASDAQ:ARTL) gapped up prior to trading on Thursday . The stock had previously closed at $1.82, but opened at $2.12. Artelo Biosciences shares last traded at $1.90, with a volume of 56,149 shares.
ARTL has been the subject of a number of analyst reports. Maxim Group raised Artelo Biosciences from a “hold” rating to a “buy” rating in a report on Thursday, January 7th. LADENBURG THALM/SH SH started coverage on Artelo Biosciences in a research note on Friday. They set a “buy” rating and a $7.00 price objective on the stock.
The firm’s 50-day moving average price is $1.01 and its two-hundred day moving average price is $0.84. The stock has a market cap of $41.79 million, a price-to-earnings ratio of -2.63 and a beta of 2.52.
Artelo Biosciences (NASDAQ:ARTL) last posted its earnings results on Wednesday, January 13th. The company reported ($0.14) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.04).
About Artelo Biosciences (NASDAQ:ARTL)
Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1 clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD.
Read More: NASDAQ Stock Market Explained
Receive News & Ratings for Artelo Biosciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Artelo Biosciences and related companies with MarketBeat.com’s FREE daily email newsletter.